Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$186M in Q4 2024 → $366M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Cg Oncology Inc | 21.9% | Added 0.1% | 1,131,500 | $80.4M |
| Urogen Pharma Ltd | 16.8% | Unchanged | 1,673,420 | $61.6M |
| Trevi Therapeutics Inc | 10.9% | Unchanged | 2,144,844 | $40M |
| Candel Therapeutics Inc | 9.8% | Unchanged | 3,497,948 | $36M |
| Puma Biotechnology Inc | 9.1% | Unchanged | 4,131,299 | $33.5M |
| JB Jade Biosceinces Inc | 6.0% | Added 25% | 986,760 | $21.9M |
| Bicara Therapeutics | 5.2% | Trimmed 0.0% | 643,381 | $19.1M |
| Karyopharm Therapeutics Inc | 4.0% | Added 427% | 1,518,113 | $14.8M |
| Onkure Therapeutics Inc | 3.5% | Unchanged | 2,839,674 | $12.9M |
| HP Helus Pharma Inc. | 2.8% | Unchanged | 1,540,266 | $10.2M |
| Protara Therapeutics Inc | 1.8% | Unchanged | 1,752,115 | $6.69M |
| Aura Biosciences Inc | 1.8% | Added 56% | 929,077 | $6.6M |
| Leonabio, Inc. | 1.6% | Unchanged | 634,539 | $5.83M |
| Verastem Inc | 1.5% | Unchanged | 1,469,153 | $5.61M |
| Whitehawk Therapeutics Inc | 1.4% | Unchanged | 1,139,363 | $5.22M |
| Q32 Bio Inc. | 0.8% | Trimmed 31% | 216,171 | $2.75M |
| ET Eugene Therapeutics | 0.6% | New | 1,271,257 | $2.2M |
| Jasper Therapeutics | 0.2% | Added 1.9% | 1,438,159 | $604K |
| Bioatla Inc | 0.1% | Trimmed 98% | 108,126 | $448K |
| VT Vyne Therapeutics Inc | 0.0% | Unchanged | 1,425 | $926 |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Terns Pharmaceuticals Inc | Exited | −1,746,264 | −$92.1M | — |
| Bioatla Inc | Trimmed | −5,298,219 | −$21.9M | 0.1% |
| Karyopharm Therapeutics Inc | Added | +1,230,287 | +$12M | 4.0% |
| JB Jade Biosceinces Inc | Added | +200,000 | +$4.44M | 6.0% |
| CO Cardif Oncology Inc | Exited | −1,762,084 | −$2.85M | — |
| Aura Biosciences Inc | Added | +333,333 | +$2.37M | 1.8% |
| ET Eugene Therapeutics | New | +1,271,257 | +$2.2M | 0.6% |
| Q32 Bio Inc. | Trimmed | −98,881 | −$1.26M | 0.8% |
| X4 Pharmaceuticals Inc | Exited | −234,039 | −$967K | — |
| Cg Oncology Inc | Added | +999 | +$71K | 21.9% |
Showing the 10 largest of 12 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| JB Jade Biosceinces Inc | New | +786,760 | +$11.1M | 3.1% |
| Candel Therapeutics Inc | Added | +917,431 | +$4.51M | 4.9% |
| Urogen Pharma Ltd | Added | +225,000 | +$4.05M | 8.6% |
| Karyopharm Therapeutics Inc | New | +287,826 | +$1.6M | 0.5% |
| Leonabio, Inc. | Added | +132,800 | +$1.37M | 1.9% |
| Q32 Bio Inc. | Trimmed | −178,373 | −$1.15M | 0.6% |
| Acrivon Therapeutics Inc | Exited | −405,237 | −$977K | — |
| Jasper Therapeutics | Trimmed | −375,000 | −$330K | 0.4% |
| CO Cardif Oncology Inc | Trimmed | −200,000 | −$324K | 0.8% |
| X4 Pharmaceuticals Inc | Trimmed | −39,310 | −$162K | 0.3% |
Showing the 10 largest of 13 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Terns Pharmaceuticals Inc | Trimmed | −225,000 | −$9.09M | 23.9% |
| Cybin Inc | Added | +838,629 | +$6.86M | 4.4% |
| Verastem Inc | Added | +689,655 | +$5.32M | 3.8% |
| Urogen Pharma Ltd | Added | +188,671 | +$4.42M | 11.5% |
| AP Athira Pharma Inc. | New | +501,739 | +$3.8M | 1.3% |
| Q32 Bio Inc. | Trimmed | −310,000 | −$1.03M | 0.6% |
| Jasper Therapeutics | Added | +403,852 | +$739K | 1.1% |
| VT Vyne Therapeutics Inc | Trimmed | −585,147 | −$340K | — |
quarter ended September 30, 2025 · filed November 17, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Y-mabs Therapeutics Inc | Exited | −3,418,995 | −$15.4M | — |
| Jasper Therapeutics | New | +1,382,640 | +$3.29M | 1.7% |
| Mural Oncology PLC | Exited | −653,779 | −$1.61M | — |
| CO Cardif Oncology Inc | Added | +553,317 | +$1.14M | 2.1% |
| X4 Pharmaceuticals Inc | Added | +119,619 | +$409K | 0.5% |
| VT Vyne Therapeutics Inc | Trimmed | −150,000 | −$51K | 0.1% |
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| X4 Pharmaceuticals Inc | Trimmed | −7,156,920 | −$13.6M | 0.2% |
| Optinose Inc | Exited | −422,814 | −$3.88M | — |
| Urogen Pharma Ltd | Trimmed | −256,554 | −$3.51M | 11.3% |
| Onkure Therapeutics Inc | Added | +1,400,000 | +$3.35M | 4.4% |
| Candel Therapeutics Inc | Added | +428,265 | +$2.17M | 8.5% |
| Mural Oncology PLC | Trimmed | −615,936 | −$1.52M | 1.1% |
| Protara Therapeutics Inc | Added | +472,315 | +$1.43M | 3.5% |
| Y-mabs Therapeutics Inc | Added | +183,608 | +$828K | 10.1% |
| Puma Biotechnology Inc | Added | +191,247 | +$656K | 9.3% |
| Bioatla Inc | Added | +803,065 | +$318K | 1.3% |
Showing the 10 largest of 13 changes.
quarter ended March 31, 2025 · filed May 19, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Y-mabs Therapeutics Inc | Added | +373,562 | +$1.65M | 9.6% |
| Aura Biosciences Inc | New | +590,508 | +$1.45M | 1.0% |
| Candel Therapeutics Inc | Added | +212,608 | +$1.2M | 8.1% |
| Trevi Therapeutics Inc | Added | +143,796 | +$904K | 9.0% |
| VT Vyne Therapeutics Inc | Added | +328,968 | +$520K | 0.8% |
| Mural Oncology PLC | Trimmed | −16,364 | −$20.6K | 1.1% |
| Whitehawk Therapeutics Inc | Trimmed | −7,689 | −$13.7K | 1.4% |
| Bicara Therapeutics | Added | +1 | +$13 | 5.6% |
| Optinose Inc | Added | +1 | +$9 | 2.6% |
| Cybin Inc | Added | +1 | +$6 | 3.1% |
Loading...
